This results in a familiar pattern: mechanistically orthogonal pairs delivering striking tumor cytoreduction preclinically (e.g., venetoclax + FLT3 inhibitors) falter under clinical dose reductions, schedule truncations, or unplanned holds, as seen in early-phase trials. The gene discussed is FLT3; the disease is neoplasm.